Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History MGTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics MGTX

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

MeiraGTx Holdings PLC

MGTX
Current price
8.62 USD -0.13 USD (-1.49%)
Last closed 8.62 USD
ISIN KYG596651029
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 692 749 760 USD
Yield for 12 month +85.38 %
1Y
3Y
5Y
10Y
15Y
MGTX
21.11.2021 - 28.11.2021

MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York. Address: 450 East 29th Street, New York, NY, United States, 10016

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

27.50 USD

P/E Ratio

Dividend Yield

Financials MGTX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures MGTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+33 279 000 USD

Last Year

+14 017 000 USD

Current Quarter

+1 926 000 USD

Last Quarter

+21 390 000 USD

Current Year

+9 488 000 USD

Last Year

+14 017 000 USD

Current Quarter

+548 000 USD

Last Quarter

+16 081 000 USD
EBITDA -146 402 000 USD
Operating Margin TTM -2 159.71 %
Price to Earnings
Return On Assets TTM -37.28 %
PEG Ratio
Return On Equity TTM -216.14 %
Wall Street Target Price 27.50 USD
Revenue TTM 34 508 000 USD
Book Value 0.42 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 176.30 %
Dividend Yield
Gross Profit TTM 9 339 000 USD
Earnings per share -2.31 USD
Diluted Eps TTM -2.31 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation MGTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 1.61
Enterprise Value Revenue 20.37
Price Sales TTM 20.08
Enterprise Value EBITDA -3.29
Price Book MRQ 20.81

Technical Indicators MGTX

For 52 Weeks

3.85 USD 8.98 USD
50 Day MA 6.24 USD
Shares Short Prior Month 3 669 151
200 Day MA 6.18 USD
Short Ratio 6.81
Shares Short 3 730 140
Short Percent 7.09 %